These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7427962)

  • 1. Tamoxifen therapy in premenopausal patients with metastatic breast cancer.
    Pritchard KI; Thomson DB; Myers RE; Sutherland DJ; Mobbs BG; Meakin JW
    Cancer Treat Rep; 1980; 64(6-7):787-96. PubMed ID: 7427962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma.
    Sawka CA; Pritchard KI; Paterson AH; Sutherland DJ; Thomson DB; Shelley WE; Myers RE; Mobbs BG; Malkin A; Meakin JW
    Cancer Res; 1986 Jun; 46(6):3152-6. PubMed ID: 3084082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen therapy in premenopausal women with metastatic breast cancer.
    Planting AS; Alexieva-Figusch J; Blonk-vdWijst J; van Putten WL
    Cancer Treat Rep; 1985 Apr; 69(4):363-8. PubMed ID: 3995508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer and neoadjuvant therapy: any predictive marker?
    Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
    Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
    Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
    Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroid receptor expression in endometria from women treated with tamoxifen.
    Kommoss F; Karck U; Prömpeler H; Pfisterer J; Kirkpatrick CJ
    Gynecol Oncol; 1998 Aug; 70(2):188-91. PubMed ID: 9740688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
    Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
    J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen and progesterone receptors in the endometrium of postmenopausal breast cancer patients treated with tamoxifen and progestogens.
    Cohen I; Altaras MM; Beyth Y; Shapira J; Figer A; Tepper R; Cordoba M; Yigal D; Bernheim J
    Gynecol Oncol; 1997 Apr; 65(1):83-8. PubMed ID: 9103396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
    Makris A; Powles TJ; Dowsett M; Osborne CK; Trott PA; Fernando IN; Ashley SE; Ormerod MG; Titley JC; Gregory RK; Allred DC
    Clin Cancer Res; 1997 Apr; 3(4):593-600. PubMed ID: 9815725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients.
    Stendahl M; Rydén L; Nordenskjöld B; Jönsson PE; Landberg G; Jirström K
    Clin Cancer Res; 2006 Aug; 12(15):4614-8. PubMed ID: 16899609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group
    J Natl Cancer Inst; 2007 Apr; 99(7):516-25. PubMed ID: 17405996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment.
    Howell A; Harland RN; Barnes DM; Baildam AD; Wilkinson MJ; Hayward E; Swindell R; Sellwood RA
    Cancer Res; 1987 Jan; 47(1):300-4. PubMed ID: 3791215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of tamoxifen in advanced male breast cancer.
    Patterson JS; Battersby LA; Bach BK
    Cancer Treat Rep; 1980; 64(6-7):801-4. PubMed ID: 7427964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of response to tamoxifen among Iraqi patients with advanced breast cancer.
    al-Alwan NA; al-Kubaisy W; al-Rawaq K
    East Mediterr Health J; 2000; 6(2-3):475-82. PubMed ID: 11556039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
    Honma N; Horii R; Iwase T; Saji S; Younes M; Takubo K; Matsuura M; Ito Y; Akiyama F; Sakamoto G
    J Clin Oncol; 2008 Aug; 26(22):3727-34. PubMed ID: 18669459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen and oophorectomy in the treatment of recurrent breast cancer: a Southwest Oncology Group Study.
    Hoogstraten B; Fletcher WS; Gad-el-Mawla N; Maloney T; Altman SJ; Vaughn CB; Foulkes MA
    Cancer Res; 1982 Nov; 42(11):4788-91. PubMed ID: 7127314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.